SCHEMBL1818486

SCHEMBL1818486

O=C(O)[C@@H]1CCCN1C(c1ccccc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KDM4E B2RXH2 2/20 0.46
CNR1 P21554 2/20 0.46
CNR2 P34972 2/20 0.46
CACNA1A O00555 1/20 0.44
CACNA2D1 P54289 1/20 0.44
CACNB1 Q02641 1/20 0.44
CACNA1C Q13936 1/20 0.44
NPSR1 Q6W5P4 3/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 2/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 2/20 0.43
CYP2D6 P10635 1/20 0.43
ITGB3 P05106 1/20 0.43
ITGB1 P05556 1/20 0.43
ITGAV P06756 1/20 0.43
ITGA5 P08648 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2032193 1.00 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2KDM4ECNR1CNR2
SCHEMBL5685739 0.90 ALDH1A1 (0.47) ALDH1A1KDM4ECNR1CNR2CACNA1A
SCHEMBL5685826 0.90 ALDH1A1 (0.47) ALDH1A1KDM4ECNR1CNR2CACNA1A
SCHEMBL5685743 0.90 ALDH1A1 (0.47) ALDH1A1KDM4ECNR1CNR2CACNA1A
SCHEMBL24359266 0.88 SLC6A9 (0.49) ALDH1A1SMN1; SMN2KDM4EMAPTITGB3
SCHEMBL24359262 0.87 KMT2A (0.45) ALDH1A1KDM4ECNR1CNR2NPSR1
SCHEMBL7305362 0.87 KMT2A (0.45) ALDH1A1KDM4ECNR1CNR2NPSR1
SCHEMBL7973302 0.84 KDM4E (0.47) ALDH1A1SMN1; SMN2KDM4EKMT2AHTT
SCHEMBL7973454 0.84 KDM4E (0.47) ALDH1A1SMN1; SMN2KDM4EKMT2AHTT
SCHEMBL7976128 0.84 KDM4E (0.47) ALDH1A1SMN1; SMN2KDM4EKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3154568-A1 NON-CANONICAL INSULINS AND THEIR USES California Institute of Technology (US) 2017-04-19 EP claimed
WO-2015191705-A1 NON-CANONICAL INSULINS AND THEIR USES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2015-12-17 WO claimed
US-20150353619-A1 Non-Canonical Insulins and Their Uses CALIFORNIA INSTITUTE OF TECHNOLOGY 2015-12-10 US claimed
EP-4694932-A2 COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS Protomer Technologies Inc. (US) 2026-02-18 EP disclosed
US-20250249074-A1 GLUCOSE RESPONSIVE INSULINS PROTOMER TECHNOLOGIES INC. 2025-08-07 US disclosed
US-20250108031-A1 FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO BACH BIOSCIENCES, LLC 2025-04-03 US disclosed
EP-4525919-A1 AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS Protomer Technologies Inc. (US) 2025-03-26 EP disclosed
US-12214018-B2 Glucose responsive insulins PROTOMER TECHNOLOGIES, INC. (US) 2025-02-04 US disclosed
US-20240425528-A1 AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS PROTOMER TECH INC (US) 2024-12-26 US disclosed
US-20240400637-A1 COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS PROTOMER TECHNOLOGIES INC. 2024-12-05 US disclosed
US-20240374735-A1 AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS PROTOMER TECHNOLOGIES INC. 2024-11-14 US disclosed
US-20080176763-A1 Collection of Traceable Compounds and Uses Thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2008-07-24 US disclosed
US-20080057491-A1 Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-03-06 US disclosed
WO-2008022015-A2 RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2008-02-21 WO disclosed
WO-2007146104-A2 SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE MCKEE PATRICK A (US) 2007-12-21 WO disclosed
EP-1756119-B1 COLLECTION OF TRACEABLE COMPOUNDS AND USES THEREOF CENTRE NAT RECH SCIENT (FR) 2007-10-10 EP disclosed
WO-2007055950-A2 POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF AERIS THERAPEUTICS, INC. (US) 2007-05-18 WO disclosed
US-20070110813-A1 Polycation-polyanion complexes, compositions and methods of use thereof AERIS THERAPEUTICS, INC. (US) 2007-05-17 US disclosed
EP-1756119-A1 COLLECTION OF TRACEABLE COMPOUNDS AND USES THEREOF Centre National de la Recherche Scientifique (FR) 2007-02-28 EP disclosed
WO-2006003329-A1 COLLECTION OF TRACEABLE COMPOUNDS AND USES THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250108031-A1 FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO FAP, FIBP, GOT1 ALDH1A1 749/4885SMN1; SMN2 3352/4885KDM4E 2409/4885
US-20250249074-A1 GLUCOSE RESPONSIVE INSULINS GLP1R, GPR119, IAPP ALDH1A1 4429/4885SMN1; SMN2 1298/4885KDM4E 3586/4885
US-20240425528-A1 AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS IAPP, GPR119, INSR ALDH1A1 4080/4885SMN1; SMN2 775/4885KDM4E 3340/4885
US-12214018-B2 Glucose responsive insulins GLP1R, GPR119, IAPP ALDH1A1 4504/4885SMN1; SMN2 1263/4885KDM4E 3625/4885
US-20150353619-A1 Non-Canonical Insulins and Their Uses IAPP, IDE, INSR ALDH1A1 4779/4885SMN1; SMN2 1833/4885KDM4E 3855/4885
US-20240400637-A1 COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS GPR119, INSR, IAPP ALDH1A1 2131/4885SMN1; SMN2 544/4885KDM4E 3404/4885
US-20240374735-A1 AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS IAPP, GPR119, BRCA1 ALDH1A1 2947/4885SMN1; SMN2 365/4885KDM4E 2803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.